Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/122089
Title: Targeting cannabinoid CB2 receptors in the Central Nervous System. Medicinal chemistry approaches and focus on neurodegenerative disorders affecting movement
Author: Navarro Brugal, Gemma
Morales, Paula
Rodríguez Cueto, Carmen
Fernández-Ruiz, Javier
Jagerovic, Nadine
Franco Fernández, Rafael
Keywords: Malalties neurodegeneratives
Receptors cel·lulars
Neurodegenerative Diseases
Cell receptors
Issue Date: 13-Sep-2016
Publisher: Frontiers Media
Abstract: Endocannabinoids activate two types of specific G-protein-coupled receptors (GPCRs), namely cannabinoid CB1 and CB2. Contrary to the psychotropic actions of agonists of CB1 receptors, and serious side effects of the selective antagonists of this receptor, drugs acting on CB2 receptors appear as promising drugs to combat CNS diseases (Parkinson's disease, Huntington's chorea, cerebellar ataxia, amyotrohic lateral sclerosis). Differential localization of CB2 receptors in neural cell types and upregulation in neuroinflammation are keys to understand the therapeutic potential in inter alia diseases that imply progressive neurodegeneration. Medicinal chemistry approaches are now engaged to develop imaging tools to map receptors in the living human brain, to develop more efficacious agonists, and to investigate the possibility to develop allosteric modulators.
Note: Reproducció del document publicat a: https://doi.org/10.3389/fnins.2016.00406
It is part of: Frontiers in Neuroscience, 2016, vol. 10
URI: http://hdl.handle.net/2445/122089
Related resource: https://doi.org/10.3389/fnins.2016.00406
ISSN: 1662-4548
Appears in Collections:Articles publicats en revistes (Bioquímica i Biomedicina Molecular)
Articles publicats en revistes (Bioquímica i Fisiologia)

Files in This Item:
File Description SizeFormat 
674564.pdf1.47 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons